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Background: Malignant melanoma is the most lethal form of skin cancer with a variable clinical course even in
patients with thin melanomas and localized disease. Despite increasing insights into melanoma biology, no
prognostic biomarkers have yet been incorporated into clinical protocols. Reduced expression of the RNA binding
motif protein 3 (RBM3) has been shown to correlate with tumour progression and poor prognosis in melanoma
and several other cancer forms. In ovarian cancer, an inverse association was found between expression of RBM3
and the minichromosome maintenance 3 (MCM3) gene and protein. In melanoma, gene expression analysis and
immunohistochemical validation has uncovered MCM3 as a putative prognostic biomarker. The aim of the present
study was to examine the associations of MCM3 expression with clinical outcome and RBM3 expression in a
prospective, population-based cohort of melanoma.
Methods: Immunohistochemical MCM3 expression was examined in 224 incident cases of primary melanoma from
the Malmö Diet and Cancer Study, previously analysed for RBM3 expression. Spearman´s Rho and Chi-Square tests
were used to explore correlations between MCM3 expression, clinicopathological factors, and expression of RBM3
and Ki67. Kaplan Meier analysis, the log rank test, and univariable and multivariable Cox proportional hazards
modelling were used to assess the impact of MCM3 expression on disease-free survival (DFS) and melanoma-
specific survival (MSS).
Results: High MCM3 expression was significantly associated with unfavourable clinicopathological features and
high Ki67 expression. A significant inverse correlation was seen between expression of MCM3 and RBM3 (p = 0.025).
High MCM3 expression was associated with a reduced DFS (HR = 5.62) and MSS (HR = 6.03), and these associations
remained significant in multivariable analysis, adjusted for all other factors (HR = 5.01 for DFS and HR= 4.96 for MSS).
RBM3 expression remained an independent prognostic factor for MSS but not DFS in the multivariable model.
Conclusions: These findings provide validation of the utility of MCM3 expression as an independent biomarker for
prognostication of patients with primary melanoma. Moreover, the inverse association and prognostic impact of
MCM3 and RBM3 expression indicate a possible interaction of these proteins in melanoma progression, the
functional basis for which merits further study.
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Malignant melanoma is an aggressive form of cancer
with an increasing incidence and mortality worldwide
[1]. Once a patient has moved into the stage of general-
ized disease, survival is very poor [2,3], but the clinical
course of melanoma is highly variable even in patients
with thin melanomas and localized disease [4-6]. Despite
increasing insights into melanoma biology and advances
in various “omics” technologies [7-9], no prognostic bio-
markers have yet been incorporated into clinical proto-
cols. We have previously demonstrated that high nuclear
expression of the RNA binding motif protein 3 (RBM3)
is associated with an improved outcome in several major
cancer forms, i.e. breast, ovarian, colorectal and prostate
cancer and malignant melanoma [10-14]. In malignant
melanoma, a significantly downregulated expression of
RBM3 was observed in metastases compared to primary
melanoma [12], which is in line with previous in vitro
data demonstrating a significant downregulation of
RBM3 expression in metastatic compared to primary
melanoma cells [15]. The functional basis for the
observed associations of loss of RBM3 expression with
tumour progression and poor prognosis in human can-
cer remains largely unclear, but in epithelial ovarian can-
cer (EOC), the association of RBM3 expression and
improved outcome has to some extent been corrobo-
rated by in vitro data demonstrating an association be-
tween RBM3 expression and improved response to
cisplatin treatment [11]. Moreover, gene set enrichment
analysis (GSEA) in human EOC has revealed an associ-
ation between RBM3 expression and several processes
involved in maintenance of DNA integrity and repair
[16]. Specifically, an inverse association was observed be-
tween expression of RBM3 and the minichromosome
maintenance 3 (MCM3) gene and protein in human
EOC samples and in ovarian cancer cells, and high ex-
pression of MCM3 was also demonstrated to be asso-
ciated with poor prognosis in EOC, both at the mRNA
and protein levels [16]. MCM proteins (MCM2-7) con-
stitute a family of highly conserved DNA-binding pro-
teins with essential functions in the initiation and
regulation of DNA replication [17,18]. In malignant mel-
anoma, gene expression analysis and independent
immunohistochemical validation have uncovered several
MCM family members, i.e. MCM3, MCM4 and MCM6
as biomarkers of poor prognosis [8]. MCM3 expression
has also been asssociated with poor prognosis in malig-
nant glioma [19] and medulloblastoma [20].
In light of the findings of an inverse association be-
tween expression of MCM3 and RBM3 in EOC, and
their prognostic implications in melanoma, the aim of
the present study was to examine the associations of
immunohistochemical MCM3 expression with expres-
sion of RBM3, clinicopathological factors and survival ina prospective, population-based cohort of malignant




Until end of follow-up 31 December 2008, 264 incident
cases of malignant melanoma had been registered in the
prospective, population-based cohort study Malmö Diet
and Cancer Study (MDCS) [21]. Cases were identified
from the Swedish Cancer Registry up until 31 Dec 2007,
and from The Southern Swedish Regional Tumour
Registry for the period of 1 Jan-31 Dec 2008. Nine
(3.4 %) cases for whom clinical and pathology records
were missing were excluded from the study, leaving 255
cases available for analysis. All tumours with available
slides and/or paraffin blocks were histopathologically re-
evaluated on haematoxylin and eosin stained slides
whereby information on lymphocytic infiltration (none,
mild, moderate or brisk), ulceration (absent or present),
mitotic count and vascular invasion was obtained. Data
on location, Clark level and Breslow depth of invasion
was obtained from the clinical- and/or pathology
records. Information on recurrence (local, regional or
distant) was obtained in 2010 from patient records and
pathology reports. Information on vital status and cause
of death was obtained from the Swedish Cause of Death
Registry up until 31 Dec 2009. Follow-up started at date
of diagnosis and ended at death, emigration or 31 Dec
2009, whichever came first. Median follow-up time was
6.84 years (range 0.64-17.05) for the full cohort (n = 255)
and 7.29 years (range 1.10-17.05) for patients alive
(n = 202). Patient and tumour characteristics of the co-
hort have been described in detail previously [12,22].
Ethical permission was obtained from the Ethics Com-
mittee at Lund University for the MDCS (Ref. 51/90),
and the present study (Ref. 530/2008).
Tissue microarray construction, immunohistochemistry
and evaluation of MCM3 staining
Paraffin-embedded tumour specimens were collected
from the archives of the pathology departments in the
region of Skåne in southern Sweden. Tumours with an
insufficient amount of material were excluded whereby
226/255 (88.6 %) cases were suitable for TMA construc-
tion. Areas representative of cancer were then marked
on haematoxylin & eosin stained slides and TMAs con-
structed as previously described [12]. In brief, three
0,6 mm cores were taken from each tumour and
mounted in a new recipient block using semi-automated
arraying device (TMArrayer, Pathology Devices, West-
minster, MD, USA). In addition, metastases (represent-
ing both regional and distant metastases in various
organs) were sampled from 31 cases, for some of which
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TMA cores was ascertained with immunohistcohemical
staining for Melan-A. For immunohistochemical analysis
of MCM3 expression, 4 um TMA-sections were auto-
matically pre-treated using the PT-link system (DAKO,
Glostrup, Denmark) and then stained in an Autostainer
Plus (DAKO) using a polyclonal MCM3-antibody
(HPA004789, diluted 1:700). MCM3 is expressed in the
nucleus and both the fraction of positive cells and stain-
ing intensity were taken into account. Nuclear fraction
was categorized into four groups, namely 0 (0-1 %), 1
(2-25 %), 2 (26–75) and 3 (> 75 %) and nuclear stain-
ing intensity denoted as 0–3, whereby 0 = negative,
1 = intermediate, 2 =moderate and 3 = strong intensity.
A combined nuclear score (NS) was then constructed
as a multiplier of MCM3 nuclear fraction and inten-
sity, thus ranging from 0 to 9. MCM3 expression was
also evaluated on a subset of full-face sections (n = 20).
Ovarian cancer samples known to have high and nega-
tive MCM3 expression[16] were included as controls,
as well as normal liver (negative control) and human
tonsil (positive control) (www.proteinatlas.org). The
immunohistochemical staining was evaluated by three
independent observers (BN, MF and KJ), including one
board certified pathologist (KJ), who were blinded to
clinical and outcome data. Scoring differences were
discussed in order to reach consensus.
Immunohistochemical staining and analysis of RBM3
and Ki67 expression was performed as previously
described [12,22].
Statistical analysis
Chi-square, Spearman´s Rho and Mann Whitney U tests
were used for correlation analyses of MCM3 expression
with clinicopathological characteristics and expression of
RBM3 and Ki67. Disease-free survival (DFS) time was
determined from the date of diagnosis of the primary
melanoma to the date of diagnosis of the first local, re-
gional or distant recurrence or death from malignant
melanoma. Follow-up started at date of diagnosis and
ended at recurrent disease, death, lost to follow-up (emi-
gration) or last date of follow-up with regard to recur-
rent disease. No recurrences were recorded following
the last date of follow-up regarding death, i.e. 31 Dec
2009. The kappa-test was used to compare the reliability
of TMA-based vs full-face section based scoring of
MCM3. Kaplan-Meier analysis and log rank test were
used to illustrate differences in DFS and melanoma-
specific survival (MSS). Cox regression proportional
hazards models were used to estimate the impact of the
investigated parameters on DFS and MSS in both uni-
and multivariable analysis. Some subjects had no infor-
mation on one or several markers and missing values
were coded as a separate category for categoricalvariables and as the mean of all observations for con-
tinuous variables. Missing values for categorical variables
co-varied and the multivariable model did not converge
due to many constant values. In order to avoid this, the
multivariable analysis only included patients with infor-
mation on MCM3 expression. Co-variates were entered
into the multivariable analysis using backward selection
where a p-value of 0.05 decided entry and a p-value of
0.10 was used for removal. All calculations were per-
formed using IBM SPSS Statistics Version 20 (SPSS Inc,
Chicago, IL). All statistical tests were two-sided and a
p value< 0.05 was considered statistically significant.
Results
Distribution of MCM3 expression in primary and
metastatic melanoma
MCM3 expression could be evaluated in 224/226
(99.1 %) primary tumours and 29/31 (93.5 %) metastases.
The non-evaluated cases did not contain sufficient
amount of tumour. Twentysix (11.6 %) primary tumours
and 2 (6.9 %) metastases lacked RBM3 expression and in
the remaining cases, MCM3 was expressed in various
fractions and intensities as demonstrated by the distribu-
tion of the nuclear score in Figure 1a and b. In contrast
to RBM3 [12], there was no significant difference in
MCM3 expression (nuclear score) in paired primary
melanoma and metastatic lesions (Spearman´s Rho =
0.24; p = 0.205). There was an excellent correlation
betweeen estimation of the nuclear score in TMA-cores
and full-face sections (kappa-value: 0.89). Sample immu-
nohistochemical images of primary tumours and paired
metachronous metastases are shown in Figure 1c-h.
Prognostic value of MCM3 expression and associaton
with clinicopathological factors
Next, we examined the prognostic value of MCM3 ex-
pression in strata according to the nuclear fraction, nu-
clear intensity, nuclear score and a dichotomized
variable of low (NS<=3) and high (NS> 3) MCM3 ex-
pression. As demonstrated in Figure 2, Kaplan-Meier
analysis revealed a stepwise decreased DFS and MSS
with increasing fractions and intensities of MCM3 ex-
pression (Figure 2a, b, e, f ). Survival analysis in strata
according to NS revealed a similar prognosis for patients
with tumours having a NS<=3 and >3, respectively
(Figure 2c, g), thus forming basis for selection of cutoff
for a dichotomized variable of low (NS>=3) vs high (NS
> 3) MCM3 expression (Figure 2d, h). Notably, none of
the patients with melanomas lacking MCM3 expression
had recurrent disease or died from melanoma.
Associations between low and high MCM3 expression,
established prognostic factors and RBM3 expression are
shown in Table 1. High MCM3 expression was signifi-
cantly associated with unfavourable clinicopathological
Figure 1 Distribution and sample immunohistochemical images of MCM3 expression in primary and metastatic melanoma. Distribution
of immunohistochemical MCM3 expression denoted as the multiplier of fraction and intensity of staining (nuclear score =NS) in a) primary
melanoma and b) metastases. Sample images of MCM3 expression in primary tumour and paired metachronous metastasis: c) nodular melanoma
on left ear (NS= 2) and d) lymph node metastasis in left groin (NS = 0); e) superficial spreading melanoma on lower left leg (NS = 6) and g)
cutaneous metastasis on back of neck (NS = 4); nodular melanoma on lower right leg (NS = 6) and cutaneous metastasis on lower right leg
(NS = 9).
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(p< 0.001), Clark level (p< 0.001), clinical stage
(p= 0.003), vascular invasion (p= 0.016), mitotic count
(p< 0.001), and high Ki67 expression (p= 0.001). A sig-
nificant inverse association was seen between expression
of MCM3 and RBM3 (p= 0.025). In metastatic melan-
oma, no significant association was observed between ex-
pression of MCM3 and RBM3 (data not shown). There
was no significant association between RBM3 and Ki67
expression in primary melanomas (data not shown).The prognostic value of MCM3 was confirmed in uni-
variable Cox regression analysis (Table 2) and remained
significant in a multivariable model, adjusted for clinico-
pathological factors, Ki67 and RBM3 expression
(Table 2). Notably, while only MCM3 expression
remained prognostic for DFS, both high MCM3 expres-
sion and low RBM3 expression remained independent
factors of a shorter MSS. MCM3 expression was asso-
ciated with a significantly reduced overall survival (OS)
in univariable analysis, but not in multivariable analysis
Figure 2 Kaplan-Meier estimates of the impact of MCM3 expression on disease free and melanoma-specific survival. Disease survival in
strata according to (a) the fraction of staining, logrank p <0.001, (b) intensity of staining, logrank p =0.001, (c) nuclear score, logrank p< 0.001,
and (d) low vs high staining, logrank p< 0.001. Melanoma-specific survival in strata according to (e) the fraction of staining, logrank p <0.001, (f)
intensity of staining, logrank p = 0.053, (g) nuclear score, logrank p< 0.003, and (h) high vs low staining, logrank p< 0.001. The nuclear score
refers to a multiplier of fraction and intensity. Low MCM3 expression refers to tumours with a nuclear score ≤3 and high expression to tumours
with a nuclear score >3.
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[12], the prognostic impact of RBM3 expression on OS
was lost when MCM3 was included in the model (data
not shown). The prognostic value of MCM3 did not dif-
fer according to gender (data not shown).
The prognostic value of MCM3 expression in thin
melanomas (≤ 1 mm; n = 137) was also examined. As
visualized in Figure 3, Kaplan Meier analysis revealed a
significant association between high MCM3 expression
and a reduced DFS (Figure 3a) and MSS (Figure 3b).
These associations were confirmed in univariable Cox
regression analysis for both DFS (HR=5.23, 95 % CI
1.35-19.23) and MSS (HR= 9.63, 95 % CI 1.07-86.44).
RBM3 expression has previously been shown not to be
prognostic in thin melanomas ≤ 1 mm [12]. Due to the
small number of events, multivariable analysis could not
be performed for MSS, but for DFS, only nodular sub-
type remained an independent prognostic factor (HR=
6.37; 95 % CI 1.19-34.03) and MCM3 expression did not
remain significant (HR= 3.74;95 % CI 0.85-16.41).
Survival according to categories of MCM3 and RBM3
expression
In light of the observed inverse association between ex-
pression of MCM3 and RBM3 in primary melanoma, we
also examined differences in survival according tocombined categories of low and high MCM3 and RBM3
expression (Figure 4). Kaplan Meier analysis revealed
that the combination of high MCM3/low RBM3 expres-
sion was associated with the poorest DFS (Figure 4a)
and MSS (Figure 4b) and the combination of high
MCM3/low RBM3 expression with the best survival,
with somewhat differing outcome for patients with
tumours expressing either low or high levels of both
markers, depending on the survival endpoint.
Discussion
In this study, we have demonstrated that high immuno-
histochemical expression of MCM3 is an independent
predictor of an increased risk of recurrence and death
from melanoma in a large, prospective, population-based
cohort study. These findings are in line with previous
results from gene expression analysis and immunohisto-
chemical validation in retrospective melanoma cohorts,
where MCM3, together with MCM4 and MCM6, was
found to correlate with poor outcome, although only
MCM4 and MCM6 remained independent predictors of
survival in multivariable analysis [8]. While we are not
aware of any other validatory studies on the prognostic
value of MCM3 expression in melanoma, a recent study
failed to confirm the prognostic value of MCM4 in a
consecutive cohort of nodular melanoma (n = 220) [23].
Table 1 Associations between MCM3 expression and
clinicopathological factors
MCM3 expression
Factor Low High P






Dorsal trunk 33 (26.0) 23 (25.6)
Frontal trunk 16 (12.6) 12 (13.3)
Arms 22 (17.3) 18 (20.0)
Legs 37 (29.1) 23 (25.6)
Head and neck 19 (15.0) 14 (15.6)
Unknown 6 1
Histological subtype 0.003
SSM 89 (66.9) 53 (58.9)
LMM 18 (13.5) 5 (5.6)
NMM 23 (17.3) 30 (33.3)








≤ 1 mm 93 (70.5) 44 (48.9)
1.1-2.0 mm 19 (14.4) 15 (16.7)
2.1-4.0 mm 14 (10.6) 23 (25.6)
> 4.0 mm 6 (4.5) 8 (8.9)
Unknown 1 1
Clark level <0.001
II 58 (43.9) 19 (21.3)
III 58 (43.9) 39 (43.8)
IV-V 16 (12.1) 31 (34.8)
Unknown 1 2
Ulceration <0.001
No 122 (91.7) 67 (74.4)
Yes 11 (8.3) 23 (25.6)
Unknown 1
Clinical stage 0.003
1 108 (91.5) 50 (75.8)
2-4 10 (8.6) 16 (24.2)
Unknown 15 24
Table 1 Associations between MCM3 expression and
clinicopathological factors (Continued)
Vascular invasion 0.016
No 129 (97.0) 81 (89.0)
Yes 4 (3.0) 10 (11.0)
Mitotic count <0.001
0/mm2 87 (65.4) 27 (29.7)
>= 1/mm2 46 (34.6) 64 (70.3)
Lymphocytic infiltrate 0.463
None-mild 40 (30.5) 23 (25.6)
Moderate-brisk 93 (69.9) 67 (74.4)
Unknown 1
Ki67 expression 0.001
Low 100 (85.5) 58 (65.9)
High 17 (14.5) 30 (34.1)
Unknown 16 3
RBM3 expression 0.025
Low 46 (37.4) 48 (52.7)
High 77 (62.6) 43 (47.3)
Unknown 10 0
P-values refer to Mann Whitney U test for comparison of medians and Chi
square test for X × 2 tables. The categories marked as unknown were not
included in the analysis.
Low RBM3 expression corresponds to a nuclear staining intensity of negative
to moderate and high expression corresponds to strong staining as previously
described [12].
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that study, the results may however not be applicable to
the general population. In our study, MCM3 expression
was strongly associated with nearly all unfavourable clin-
icopathological characteristics and, yet, remained an in-
dependent predictor of a reduced DFS and MSS,
adjusted for all other factors. As denoted and discussed
previously, the proportion of thin melanomas in this co-
hort is higher than the expected [12], despite the higher
age of participants in the MDCS (all> 40 years at study
entry) and the fact that older melanoma patients more
frequently present with advanced disease [24]. Neverthe-
less, as current clinical guidelines in Sweden recommend
sentinel node biopsy only in melanomas> 1 mm, there
is a great unmet need for identification of prognostic
biomarkers in thin melanomas (≤ 1 mm) [25], not least
since this category seems to make up for most of the in-
creasing melanoma incidence [26]. Therefore, despite
the possibility of a selection bias and the small number
of events, the comparatively large proportion of thin
melanomas in the MDCS may offer some advantage in
biomarker studies. The study by Winnepenninckx et al.
was limited to melanomas in the vertical growth phase
and/or with a thickness of> 1 mm [8] and, notably, in
our study, MCM3 expression was found to be prognostic
Table 2 Relative risks of recurrent disease and death from melanoma according to MCM3 expression
Risk of disease recurrence Risk of death from melanoma
Univariable Multivariable Univariable Multivariable
n (events) HR (95%CI) HR (95%CI) n (events) HR (95%CI) HR (95%CI)
Age
Continuous 255 (47) 1.01 (0.97-1.05) 255 (28) 1.05 (0.99-1.10) 1.08 (1.02-1.14)
Gender
Female 132 (21) 1,00 132 (9) 1,00
Male 123 (26) 1.51 (0.85-2.70) 123 (19) 2.77 (1.25-6.14)
Clark level
II 93 (5) 1,00 93 (2) 1,00
III 103 (21) 4.39 (1.65-11.65) 103 (14) 7.16 (1.63-31.50)
IV-V 51 (21) 9.99 (3.76-26.55) 51 (12) 12.91 (2.89-57.74)
Breslow
Continuous 248 (47) 1.07 (1.03-1.11) 248 (28) 1.08 (1.03-1.13)
Subtype
SSM, LMM, Other 195 (22) 1,00 195 (11) 1,00 1.00
Nodular 53 (24) 5.63 (3.15-10.08) 53 (16) 7.19 (3.32-15.57) 5.51 (2.39-12.71)
Ulceration
No 214 (30) 1,00 214 (18) 1,00
Yes 35 (16) 5.81 (3.13-10.80) 35 (9) 5.73 (2.59-12.97)
Lymphocytic
infiltrate
0-1 72 (20) 1,00 72 (11) 1,00
2-3 176 (26) 0.43 (0.24-0.78) 176 (16) 0.50 (0.23-1.08)
Clinical stage
I 179 (12) 1,00 1,00 179 (7) 1,00
II-IV 28 (13) 15.02 (6.39-35.30) 12.03 (4.49-32.28) 28 (8) 14.09 (4.82-41.18)
Mitotic count
<1/mm2 131 (7) 1,00 131 (3) 1,00
>= 1/mm2 122 (40) 7.96 (3.56-17.80) 122 (25) 11.25 (3.39-37.36)
Vascular invasion
No 232 (35) 1,00 1,00 232 (18) 1,00 1.00
Yes 14 (11) 9.25 (1.67-7.60) 3.56 (2.35-10.92) 14 (9) 11.29 (5.05-25.25) 8.26 (3.30-20.67)
Ki67 expression
Low (<=25 %) 159 (28) 1,00 159 (16) 1,00
High (>25 %) 47 (16) 2.46 (1.33-4.56) 47 (10) 2.64 (1.20-5.83)
RBM3 expression
Low 95 (24) 1.00 95 (17) 1.00 1.00
High 120 (20) 0.50 (0.27-0.91) 120(9) 0.29 (0.13-0.66) 0.30 (0.14-0.71)
MCM3 expression
Low (N≤ S3) 133 (11) 1.00 1.00 133 (6) 1.00 1.00
High (NS> 3) 91 (34) 5.62 (2.83-11.13) 5.01 (0.33-10.79) 91 (21) 6.03 (2.42-15.02) 4.96 (1.77-13.87)
Low RBM3 expression corresponds to a nuclear staining intensity of negative to moderate and high expression corresponds to strong staining as previously
described [12]. The number of cases in the multivariable analysis is equal to the number of cases evaluated for MCM3 expression (n = 224).
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Figure 3 Kaplan-Meier estimates of the impact of MCM3 expression on disease free and melanoma-specific survival in thin
melanomas. The impact of low and high MCM3 expression on (a) disease free survival, logrank p = 0.007, and (b) melanoma-specific survival,
logrank p= 0.031, in thin melanoma (<= 1 mm).
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tial value of MCM3 expression as a prognostic bio-
marker in thin melanomas merits further investigation
in larger patient cohorts.Figure 4 Kaplan-Meier estimates of disease free and melanoma-speci
expression. The impact of combined categories low and high expression
and (b) melanoma-specific survival.A cautionary remark should also be made regarding
methodological aspects on the use of the TMA tech-
nique for biomarker studies in malignant melanoma,
mainly concerning the technical difficulty in sampling offic survival in combined strata of high and low MCM3 and RBM3
of MCM3 and RBM3 expression, respectively, on (a) disease free survival
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tion of clinicopathological characteristics was similar in
tumours included in the TMA cohort (n = 226) and
tumours not suitable for TMA construction (n = 29) in
the full cohort, with exception for histological subtype,
with no tumours being denoted as nodular in the cat-
egory not suitable or available for TMA construction,
but an equal distribution of the other subtypes [22]. An-
other limitation to the TMA technique is that it might
not accurately reflect the expression of heterogenously
expressed markers. Therefore, assessment of MCM3 ex-
pression was also performed in a subset of full-face sec-
tions, which resulted in a kappa-value corresponding to
the best degree of concordance [27].
The here observed inverse association of MCM3 and
RBM3, both regarding their tumour-specific expression
and impact on survival, is in line with previous in vivo
and in vitro observations in ovarian cancer [16]. Notably,
MCM3 expression was an independent predictor of both
DFS and MSS while RBM3 only remained an independ-
ent predictor of CSS and OS [12]. Longitudinal analysis
did not reveal an altered expression of MCM3 in meta-
static compared to primary melanoma, in contrast to
RBM3, that was found to be downregulated in metastatic
melanoma in two independent studies, including the
present cohort [12,15]. Moreover, RBM3 expression was
not found to be prognostic in thin melanomas, but an
independent prognostic factor in melanomas thicker
than 1 mm [12]. Expression of MCM3 but not RBM3
correlated significantly with Ki67 expression, which is in
line with its role as a marker of proliferation [28,29]. In
contrast to MCM3, however, Ki67 expression was not
prognostic in the full cohort in our previous study, only
in male melanoma [22]. Speculatively, these findings in-
dicate that loss of RBM3 may be associated with a
switch towards a more invasive and/or metastatic rather
than proliferative phenotype, while up-regulated MCM3
expression may either be associated with increased pro-
liferation or functions beyond DNA licensing, i.e. cell
migration and invasion, as demonstrated in medulloblas-
toma cells [20].
In a translational context, while MCM3 expression
appears to be a stronger prognostic biomarker than
RBM3, not least in thin melanomas, the inverse correl-
ation between tumour-specific expression of MCM3 and
RBM3, which is in line with previous observations in
ovarian cancer [16], may give some directions towards
further functional studies of the role and interaction of
these proteins in melanoma progression and metastasis.
While both proteins have been demonstrated to be up-
regulated in several premalignant conditions and cancer
forms compared to their corresponding normal tissues
[13,17,28-31], it is becoming increasingly evident that
their oncogenic activities in human tumours influenceclinical outcome in opposite ways. One explanation for
this may be that elevated expression of RBM3 attenuates
DNA damage response, in which MCM proteins play an
important role [17,32], thus preventing the selection of
clones with an increased capability for invasion and
metastatic spread [33,34]. Along this line, it would also
be of interest to study the expression of MCM3 and
RBM3 in benign naevi, dysplastic naevi and melanoma
in situ in order to assess their potential role as markers
of genetic abnormalities and high-risk lesions, for which
e.g. FISH testing has been identified as a valuable diag-
nostic tool [35]. Ladstein et al. compared MCM4 expres-
sion in benign naevi and melanoma and found
significantly higher MCM4 positivity in melanoma com-
pared to benign naevi [23].Conclusions
The findings from this prospective cohort study provide
an independent validation of MCM3 expression as a bio-
marker of poor prognosis in malignant melanoma, also
in the category of thin melanomas, which may be of par-
ticular clinical relevance. Moreover, we have demon-
strated an inverse association between tumour-specific
expression of MCM3 and the RBM3 protein, loss of
which has previously been found to correlate with
tumour progression and poor prognosis in melanoma.
The mechanistic basis for these observations should be
addressed in future studies.
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